Literature DB >> 32253275

Discontinuation of RAAS Inhibition in Children with Advanced CKD.

Sophie M van den Belt1, Hiddo J L Heerspink2, Marietta Kirchner3, Valentina Gracchi4, Daniela Thurn-Valsassina5, Aysun K Bayazit6, Anna Niemirska7, Nur Canpolat8, Ipek Kaplan Bulut9, Karolis Azukaitis10, Ali Duzova11, Justine Bacchetta12, Rukshana Shroff13, Dusan Paripovic14, Zeynep Birsin Özçakar15, Kibriya Fidan16, Hakan Erdogan17, Jutta Gellermann18, Elke Wühl19, Dick de Zeeuw2, Anette Melk5, Uwe Querfeld18, Franz Schaefer19.   

Abstract

BACKGROUND AND OBJECTIVES: Although renin-angiotensin-aldosterone system inhibition (RAASi) is a cornerstone in the treatment of children with CKD, it is sometimes discontinued when kidney function declines. We studied the reasons of RAASi discontinuation and associations between RAASi discontinuation and important risk markers of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children with CKD study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this study, 69 children with CKD (67% male, mean age 13.7 years, mean eGFR 27 ml/min per 1.73 m2) who discontinued RAASi during prospective follow-up were included. Initial change in BP, albuminuria, and potassium after discontinuation were assessed (median time 6 months). Rate of eGFR decline (eGFR slope) during a median of 1.9 years before and 1.2 years after discontinuation were estimated using linear mixed effects modeling.
RESULTS: Physician-reported reasons for RAASi discontinuation were increase in serum creatinine, hyperkalemia, and symptomatic hypotension. After discontinuation of RAASi, BP and albuminuria increased, whereas potassium decreased. eGFR declined more rapidly after discontinuation of RAASi (-3.9 ml/min per 1.73 m2 per year; 95% confidence interval, -5.1 to -2.6) compared with the slope during RAASi treatment (-1.5 ml/min per 1.73 m2 per year; 95% confidence interval, -2.4 to -0.6; P=0.005). In contrast, no change in eGFR slope was observed in a matched control cohort of patients in whom RAASi was continued.
CONCLUSIONS: Discontinuation of RAASi in children with CKD is associated with an acceleration of kidney function decline, even in advanced CKD.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  Acceleration; Blood Pressure Determination; Cohort Studies; Comorbidity; Follow-Up Studies; Hyperkalemia; Potassium; Prospective Studies; RAAS inhibition; Renal Insufficiency, Chronic; Renin-Angiotensin System; albuminuria; blood pressure; chronic renal disease; creatinine; glomerular filtration rate; hypotension; pediatric nephrology

Year:  2020        PMID: 32253275      PMCID: PMC7269205          DOI: 10.2215/CJN.09750819

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  19 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

3.  Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes.

Authors:  Hirofumi Makino; Masakazu Haneda; Tetsuya Babazono; Tatsumi Moriya; Sadayoshi Ito; Yasuhiko Iwamoto; Ryuzo Kawamori; Masahiro Takeuchi; Shigehiro Katayama
Journal:  Diabetes Care       Date:  2007-03-26       Impact factor: 19.112

4.  Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD.

Authors:  Alison G Abraham; Aisha Betoko; Jeffrey J Fadrowski; Christopher Pierce; Susan L Furth; Bradley A Warady; Alvaro Muñoz
Journal:  Pediatr Nephrol       Date:  2016-11-08       Impact factor: 3.714

5.  The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology.

Authors:  Uwe Querfeld; Ali Anarat; Aysun K Bayazit; Aysin S Bakkaloglu; Yelda Bilginer; Salim Caliskan; Mahmut Civilibal; Anke Doyon; Ali Duzova; Daniela Kracht; Mieczyslaw Litwin; Anette Melk; Sevgi Mir; Betül Sözeri; Rukshana Shroff; René Zeller; Elke Wühl; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-24       Impact factor: 8.237

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Efficacy and safety of benazepril for advanced chronic renal insufficiency.

Authors:  Fan Fan Hou; Xun Zhang; Guo Hua Zhang; Di Xie; Ping Yan Chen; Wei Ru Zhang; Jian Ping Jiang; Min Liang; Guo Bao Wang; Zheng Rong Liu; Ren Wen Geng
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

8.  Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.

Authors:  H P Hansen; P Rossing; L Tarnow; F S Nielsen; B R Jensen; H H Parving
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

9.  Strict blood-pressure control and progression of renal failure in children.

Authors:  Elke Wühl; Antonella Trivelli; Stefano Picca; Mieczyslaw Litwin; Amira Peco-Antic; Aleksandra Zurowska; Sara Testa; Augustina Jankauskiene; Sevinc Emre; Alberto Caldas-Afonso; Ali Anarat; Patrick Niaudet; Sevgi Mir; Aysin Bakkaloglu; Barbara Enke; Giovanni Montini; Ann-Margret Wingen; Peter Sallay; Nikola Jeck; Ulla Berg; Salim Caliskan; Simone Wygoda; Katharina Hohbach-Hohenfellner; Jiri Dusek; Tomasz Urasinski; Klaus Arbeiter; Thomas Neuhaus; Jutta Gellermann; Dorota Drozdz; Michel Fischbach; Kristina Möller; Marianne Wigger; Licia Peruzzi; Otto Mehls; Franz Schaefer
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

10.  Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Authors:  Sunil Bhandari; Natalie Ives; Elizabeth A Brettell; Marie Valente; Paul Cockwell; Peter S Topham; John G Cleland; Arif Khwaja; Meguid El Nahas
Journal:  Nephrol Dial Transplant       Date:  2015-09-30       Impact factor: 5.992

View more
  7 in total

1.  Benefits of Continuing RAAS Inhibitors in Advanced CKD.

Authors:  Marie-Michèle Gaudreault-Tremblay; Bethany J Foster
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 8.237

Review 2.  Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction.

Authors:  Charalampos Loutradis; Anna Price; Charles J Ferro; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2021-03-02       Impact factor: 3.012

3.  L-type calcium channel blocker use and proteinuria among children with chronic kidney diseases.

Authors:  Kelsey L Richardson; Donald J Weaver; Derek K Ng; Megan K Carroll; Susan L Furth; Bradley A Warady; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2021-02-15       Impact factor: 3.714

Review 4.  Glomerular Biomechanical Stress and Lipid Mediators during Cellular Changes Leading to Chronic Kidney Disease.

Authors:  Mukut Sharma; Vikas Singh; Ram Sharma; Arnav Koul; Ellen T McCarthy; Virginia J Savin; Trupti Joshi; Tarak Srivastava
Journal:  Biomedicines       Date:  2022-02-09

5.  Refining Kidney Survival in 383 Genetically Characterized Patients With Nephronophthisis.

Authors:  Jens Christian König; Rebeka Karsay; Joachim Gerß; Karl-Peter Schlingmann; Mareike Dahmer-Heath; Anna-Katharina Telgmann; Sabine Kollmann; Gema Ariceta; Valentine Gillion; Detlef Bockenhauer; Aurélia Bertholet-Thomas; Antonio Mastrangelo; Olivia Boyer; Marc Lilien; Stéphane Decramer; Joost P Schanstra; Martin Pohl; Raphael Schild; Stefanie Weber; Julia Hoefele; Jens Drube; Metin Cetiner; Matthias Hansen; Julia Thumfart; Burkhard Tönshoff; Sandra Habbig; Max Christoph Liebau; Martin Bald; Carsten Bergmann; Petra Pennekamp; Martin Konrad
Journal:  Kidney Int Rep       Date:  2022-06-16

Review 6.  When should we start and stop ACEi/ARB in paediatric chronic kidney disease?

Authors:  Eugene Yu-Hin Chan; Alison Lap-Tak Ma; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2020-10-14       Impact factor: 3.714

Review 7.  Clinical Management of Children with a Congenital Solitary Functioning Kidney: Overview and Recommendations.

Authors:  Sander Groen In 't Woud; Rik Westland; Wout F J Feitz; Nel Roeleveld; Joanna A E van Wijk; Loes F M van der Zanden; Michiel F Schreuder
Journal:  Eur Urol Open Sci       Date:  2021-02-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.